|35.73|| +0.47 / +1.33%|
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment involves in the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation, and therapy areas. The company was founded by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
|Lars Fruergaard Jørgensen||President & Chief Executive Officer|
|Jesper Brandgaard||Chief Financial Officer & Executive Vice President|
|Mads Krogsgaard Thomsen||Chief Science Officer & Executive Vice President|
|Mads Krogsgaard||Chief Science Officer|
|Jakob Riis||EVP & Head-North America Operations|